T cell Ig and mucin domain-containing molecule 3 (Tim-3) has been found to play important roles in autoimmune diseases, but whether Tim-3-mediated engulfment of apoptotic cells is involved in systemic lupus erythematosus (SLE) remains to be elucidated. In this study, we verified the role of human Tim-3 (hTim-3) as the receptor of phosphatidylserine (PS) in human embryonic kidney (HEK)293 cells, which initiated the engulfment of apoptotic cells. Both IgV and the mucin domain of Tim-3 were crucial in the phagocytosis of apoptotic cells, and there existed the key cytoplasmic domain for signal transduction. Alanine at 111, locating around the FG-CC9 loop of hTim-3, was necessary for its engulfment of apoptotic cells. In accordance, Tim-3 on CD14
Introduction
Human SLE is a chronic systemic autoimmune disease of largely unclear etiology that can affect many organs, characterized by producing a wide range of autoantibodies. Several lines of evidence show that increased apoptosis and impaired clearance of apoptotic cells could play important roles in the pathogenesis of SLE [1] . Studies on human SLE have suggested increased apoptosis of PBMCs and neutrophils [2, 3] . Apoptotic cells are thought to result in secondary necrosis and contribute to the pathogenic autoantibody production. The safe removal of apoptotic cell debris is a dedicated function of phagocytic cells, particularly macrophages [4, 5] . However, it is reported that macrophages from SLE patients exhibited impaired clearance of apoptotic cells both in vitro and in vivo [6] [7] [8] .
Monocytes and macrophages from SLE patients may have multiple intrinsic defects that potentially are involved in the removal of apoptotic cells, such as abnormal differentiation/survival, signaling pathway abnormalities, and altered expression of cell membrane molecules [9, 10] . Those membrane receptors involved in the uptake of apoptotic cells include the LPS receptor (CD14), complement receptors (CD11a,b,c/CD18), the thrombospondin receptor (CD36), membrane tyrosine kinase c-mer, the vitronectin receptor (CD51/ CD61), CD44, and the PS receptor [11] [12] [13] [14] . Therefore, insight into the key molecules that govern apoptotic cell engulfment may be critical to uncover the mechanisms of SLE pathogenesis.
PS is a phospholipid component, usually located on the cytosolic side of cell membranes, and becomes exposed on outer membranes when cells undergo apoptosis. The exposure of PS on the outer leaflet of cell membranes appears to be a key "eatme" marker [15, 16] that can be recognized by engulfment receptors on phagocytes and initiate the engulfment process. Two TIM family members, including Tim-1 and Tim-4, are proven to be PS recognition receptors on phagocytes and play important roles in apoptotic cell clearance [17, 18] . Tim-3, another member of the TIM family, which is a newly discovered negative costimulatory molecule [19, 20] , has been demonstrated to express constitutively on monocytes/macrophages [21] . Recently, the recognition of PS by Tim-3 was identified as the highly conserved TIM-PS interaction found in TIM/PS cocrystal structures [22] . It has been found that both mice and hTim-3 can mediate removal of apoptotic cells by interaction with PS [22, 23] . In our previous study, we detected increased mRNA expression levels of Tim-3 and its ligand galactin-9 in PBMCs from patients of SLE. Interestingly, Tim-3 expression positively correlated with IFN-g, suggesting that Tim-3 might take part in the pathogenesis of SLE [24] . Nevertheless, whether Tim-3 is involved in SLE through mediating the clearance of apoptotic cells has not yet been clarified. Nakayama et al. [22] confirmed that mouse Tim-3 internalized apoptotic cells through the FG-CC9 loop in the IgV domain. The mutation of arginine at aa 112 to alanine (R112A) of mouse Tim-3 resulted in the failure of binding with apoptotic cells, demonstrating the key function of this site [22] . However, which domain and site of hTim-3 are functional in mediating phagocytosis of apoptotic cells is still unknown.
Besides the full-length, membrane-anchored form, Tim-3 may exist as a soluble form (sTim-3) [25] . sTim-3 can be produced by either alternative splicing of Tim-3 mRNA or ectodomain shedding products of ADAM-10 and -17 [25] [26] [27] . Recently, an increased level of sTim-3 has been reported in serum from patients with HIV infection, which correlates with disease progression, indicating the important clinical relevance of sTim-3 in inflammatory diseases [25] . Yuan et al. [28] reported that decreased sTim-3 was assayed in serum from SLE patients. However, the involvement of sTim-3 in SLE is largely unknown.
In the present study, for the first time, we verified the ability of hTim-3 to promote the engulfment of apoptotic cells and identified the functional domain of hTim-3 responsible for the engulfment. Like murine Tim-3, the lack of extracellular IgV or mucin domain or mutation at R111 disrupts the ability of hTim-3 to promote apoptotic cell engulfment. Otherwise, the intracellular region of hTim-3 is absolutely essential in this process. In agreement with the ability of hTim-3 for promoting engulfment of apoptotic cells, Tim-3 expression on CD14
+ monocytes was negatively correlated with the percentage of Annexin V + cells in peripheral blood from control subjects. However, although Tim-3 expression was augmented on CD14  + cells in peripheral blood  from SLE patients, the percentage of Tim-3   +   CD14 + cells showed positive correlation with Annexin V + cells, indicating the defects of Tim-3 on macrophage-mediated engulfment of apoptotic cells. Accordingly, significantly increased sTim-3 expression was found in plasma of SLE patients; moreover, ADAM-10 mRNA expression was also increased in PBMCs of SLE patients. In addition, both plasma from SLE patients and recombinant sTim-3 weakened Tim-3-promoted phagocytosis of apoptotic cells. Our results here provide a new explanation of the pathologic mechanism of SLE, in which both full-length and sTim-3 might be involved.
MATERIALS AND METHODS

Subjects
Ninety-three incipient SLE patients fulfilling the criteria of the American College of Rheumatology were enrolled for this study [29] . Eighty-three sexand age-matched control subjects were recruited. Fresh peripheral blood cells from 44 SLE patients and 47 control subjects were used for flow cytometry assay. Peripheral blood white cells from 35 SLE patients and 41 control subjects were used for apoptosis detection, and cells from 36 SLE patients and 34 control subjects were used for analysis of Tim-3 expression. Disease activity of SLE patients was assessed by anti-dsDNA (international units per milliliter), C3 (grams per liter), C4 (grams per liter), ESR (millimeters per hour), and the SLEDAI score. We obtained 17 SLE patients with anti-dsDNA, 23 SLE patients with C3, 15 SLE patients with C4, 38 SLE patients with ESR, and 43 SLE patients with the SLEDAI scores. PBMCs from 16 SLE patients and 11 control subjects were collected for ADAM-10 and ADAM-17 detection. Plasma from 49 SLE patients and 36 control subjects was collected for sTim-3 assay. All samples were collected from Qilu Hospital of Shandong University, and incipient SLE patients were enrolled in this study to exclude the influence of immunosuppressive drugs on clinical parameters. The study received approval from the Ethics Committee of Shandong University School of Medicine, and informed consent was acquired from each individual. The characteristics of both SLE patients and control subjects are summarized in Table 1 .
Cell culture and reagents HEK293 cells (CRL-1573; ATCC, Manassas, VA, USA) and THP-1 cells (TIB-202; ATCC) were both cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FBS (Thermo Fisher Scientific) and 1% penicillin-streptomycin (Thermo Fisher Scientific) at 37°C in a humidified atmosphere containing 5% CO 2 . Recombinant plasmid DNA containing fulllength or truncated hTim-3 gene fragments was transiently transfected into HEK293 cells by using Lipofectamine 2000 (Thermo Fisher Scientific), according to the manufacturer's instructions. Twenty-four hours later, transfected HEK293 cells were incubated with apoptotic thymocytes. Tim-3 expression in transfected HEK293 cells was detected by RT-PCR, Western blot, and flow cytometry assay.
Adherent-differentiated THP-1 cells, which exhibited a macrophage-like phenotype by stimulating with 50 ng/ml PMA (Sigma-Aldrich, St. Louis, MO, USA) for 24 h, were used as phagocytes, and Tim-3 expression on THP-1 cells was detected by flow cytometry analysis.
Flow cytometry
Anticoagulated whole blood (200 ml) was used to eliminate RBCs by RBC lysis buffer (Beyotime, Shanghai, China), according to the manufacturer's instructions. WBCs were washed twice with cold PBS and resuspended in 500 ml Annexin V binding buffer containing 5 ml Annexin V and 5 ml propidium iodide (PI) (Bestbio, Shanghai, China). Then, the cells were gently vortexed and incubated for 10 min at room temperature in the dark and assayed by flow cytometry within 30 min. Anticoagulated whole blood (50 ml) was incubated with FITC-conjugated anti-human CD14 (eBioscience, San Diego, CA, USA) and PE-conjugated anti-hTim-3 (Catalog Number: FAB2365P, Clone #344823; R&D Systems, Minneapolis, MN, USA) for 30 min at 4°C in the dark and then submitted to RBC lysis using BD FACS lysis solution (BD Biosciences, San Jose, CA, USA). Transfected HEK293 or THP-1 cells were incubated with PE-conjugated anti-hTim-3 (R&D Systems) for 30 min, according to the manufacturer's instructions. At least 10,000 cells were acquired on a Beckman Coulter flow cytometer (FC500; Beckman Coulter, Brea, CA, USA), and data were analyzed using the FC500 CellQuest program. The stained THP-1 cells were detected using a BD FACSCanto Ⅱ Flow Cytometer (BD Biosciences, San Jose, CA, USA) and the data were analyzed using FACSDiva software (BD Biosciences).
ELISA for sTim-3
Plasma was collected after anticoagulated peripheral blood was centrifuged for 3 min at 1500 g and stored at 280°C. ELISA kit (SEH930Hu; Cloud-Clone, Katy, TX, USA) was used to assay sTim-3 in plasma, according to the manufacturer's instructions. The minimum detection limit was 29 pg/ml.
Plasmid construction
Full-length or truncated hTim-3 gene fragments fused with an HA-tag were amplified with PCR using the plasmid pcDNA3-hTim-3 as a template. PCR products were digested with HindIII and XhoI (Takara Biotechnology, Dalian, China) and subcloned into pcDNA3 to construct a variety of hTim-3 eukaryotic expression vectors. Plasmids containing hTim-3-FL, DIgV, Dmucin, Dcyto, and the R111A were constructed and identified successfully by DNA sequencing.
RT-PCR and Western blot
RNA was isolated from HEK293 cells or PBMCs from SLE patients and control subjects using TRIzol reagent (Thermo Fisher Scientific), according to the manufacturer's instructions. Semiquantitative RT-PCR was performed to assay Tim-3 mRNA expression, and real-time quantitative PCR was performed to detect the expression of ADAM-10 and -17, as described previously [24] . The primer sequences were summarized in Supplemental Table 1 . Transfected HEK293 cells were lysed with protein lysis buffer (Thermo Fisher Scientific), and Western blot was performed to detect Tim-3 protein expression with goat anti-hTim-3 (Catalog Number: AF2365; R&D Systems) and mouse anti-HA antibody (MBL International, Woburn, MA, USA). b-Actin was used as internal control.
Induction of thymocyte apoptosis
Thymocytes were isolated from 4-to 6-wk-old wild-type BALB/c mice and then seeded into 6-well plates at 1 3 10 7 /ml, followed by incubation with 10 mM dexamethasone (Enzo Life Sciences, Farmingdale, NY, USA) in DMEM without FBS for 4 h. Apoptotic cells were evaluated by staining with Annexin V-FITC and PI. Then, apoptotic thymocytes were dyed by 0.2 mg/ml pHrodo-SE (Thermo Fisher Scientific), which is a pH-sensitive fluorescent dye. Thirty minutes later, 1 ml FBS was added to stop dying. All of those apoptotic cells were collected and washed twice with PBS containing 2% FBS.
Phagocytosis assay
HEK293 cells were seeded in 12-well plates and transfected with different plasmid DNA containing full-length or truncated Tim-3 gene fragments. Twenty four hours later, transfected HEK293 cells were collected for phagocytosis assay. pHrodo-SE-labeled apoptotic thymocytes were then cocultured with the transfected HEK293 cells (20:1) in DMEM containing 10% FBS at 37°C for 90 min. Then, cells were washed quickly 3 times with PBS containing 2% FBS and 0.1 mM EDTA to remove free apoptotic cells. HEK293 cells were detached and resuspended in CHES(N-cyclohexyl-2-aminoethanesulfonic acid)-NaOH buffer (pH 10.1) for a fluorescence microscope or flow cytometry assay. Only internalized apoptotic cells labeled with pHrodo-SE were monitored as a result of the acidic environment in lysosome, and Red fluorescence light could be read out when transfected HEK293 cells engulfed apoptotic cells labeled with pHrodo-SE.
To evaluate the effect of sTim-3 in plasma from SLE patients on Tim-3-initiated phagocytosis of apoptotic cells, pHrodo-SE-labeled apoptotic cells were incubated with DMEM containing 20% plasma from SLE patients or control subjects for 60 min before cocultured with adherent-differentiated THP-1 cells. The plasma from SLE patients or control subjects was pretreated in a water bath at 56°C for 30 min to inactivate complement.
To confirm further the role of sTim-3 in plasma in Tim-3-mediated phagocytosis of apoptotic cells, sTim-3 in the plasma from SLE patients was depleted by incubating with the 4 mg anti-hTim-3 antibody (Catalog Number: MAB23651, Clone #344801; R&D Systems) at room temperature for 3 h, which had been conjugated to Protein A/G beads at 4°C overnight, and purified rat IgG1 was used as an isotype control. Then, pHrodo-SE-labeled apoptotic cells were incubated with sTim-3-depleted plasma from SLE patients for 60 min and cocultured with adherent-differentiated THP-1 cells (20:1) for 90 min.
To explore further the effect of sTim-3 on Tim-3-mediated phagocytosis of apoptotic cells, pHrodo-SE-labeled apoptotic cells were incubated with 30 mg/ml recombinant sTim-3 (19-C356; ARP American Research Products, Waltham, MA, USA) for 60 min and cocultured with adherent-differentiated THP-1 cells for 90 min. The phagocytosis efficiency was analyzed by a fluorescence microscope.
Fluorescence microscope measurements
Phagocytosis of apoptotic cells was measured by monitoring pHrodo-SE-Red fluorescence. Fluorescent images were taken on a Lionheart FX Automated live cell imager (BioTek, Winooski, VT, USA). Image capture, processing, and analysis were provided by Gen5 3.0 software. Relative intensity/cells analyzed by Gen5 3.0 software was used as phagocytosis efficiency.
Statistical analysis
All data were analyzed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Mann-Whitney nonparametric U test and Student's t test 
RESULTS
IgV and mucin domain, especially R111, are indispensable for hTim-3-mediated engulfment of apoptotic cells
We firstly verified the role of hTim-3 in mediating the engulfment of apoptotic cells in HEK293 cells coculturing with pHrodo-SE-labeled apoptotic cells. As shown in Fig. 1 , flow cytometry showed the hTim-3-FL overexpression in HEK293 cells (Fig. 1A) and the apoptosis of thymocytes induced by 10 mM dexamethasone (Fig. 1B) . Both fluorescence microscope (Fig.  1C) and flow cytometry analysis (Fig. 1D) confirmed that hTim-3 strongly promoted the engulfment of apoptotic cells in HEK293 cells, which is consistent with the reports from other labs [23] .
To illuminate the function of a different domain of hTim-3 in the engulfment of apoptotic cells, various hTim-3 expression constructs were prepared, including hTim-3-FL, DIgV, Dmucin, Dcyto, and R111A, all with the C-terminal HA-tag. The aligned schematic representation of different Tim-3 constructs was shown in Supplemental Fig. 1A . Tim-3 expression was verified by semiquantitative RT-PCR (Supplemental Fig. 1B ), Western blot (Supplemental Fig. 1C) , and flow cytometry (Supplemental Fig. 1D ).
As shown in Fig. 1C-E , overexpression of hTim-3-FL enabled HEK293 cells to engulf apoptotic cells, whereas HEK293 cells transfected with DIgV or Dmucin almost completely lost the ability to engulf apoptotic cells (Fig. 1D and E) . These results suggested that both IgV and mucin domains are necessary for Tim-3-mediated engulfment of apoptotic cells. Nakayama et al. [22] mutated some amino acids located around the FG-CC9 loop of mouse Tim-3 to alanine and found that substitution of Arg112 completely abrogated the activity of mouse Tim-3 mediating the phagocytosis of apoptotic cells, demonstrating the key function of this site. As its analog in mice, mutation at alanine (R111A) of hTim-3 was involved. As shown in Fig. 1D and E, mutation of R111A resulted in the dramatic decrease of engulfment of apoptotic cells in hTim-3-transfected HEK293 cells, suggesting that the R111 of hTim-3 is crucial for recognition of PS.
To understand better the functional domain of hTim-3, we generated a cytoplasmic tailless Tim-3 with the C-terminal HA-tag, which is called Dcyto. As shown in Fig. 1D and E, HEK293 cells transiently expressing tailless Tim-3 led to lower engulfment than the full-length Tim-3 group. Therefore, we supposed that the cytoplasmic tail of Tim-3 might contribute to engulfment of apoptotic cells.
Tim-3 expression on CD14
+ monocytes negatively correlates with Annexin V + cells in control subjects and positively correlates with Annexin V + cells in SLE patients
We then further evaluated the expression pattern of Tim-3 on CD14 + monocytes and analyzed the correlation of Tim-3 on CD14 + monocytes with apoptotic cells in SLE patients and control subjects. As previously reported [3, 30] , compared with control subjects, we detected a significantly higher level of Annexin V + cells in peripheral blood from SLE patients ( Fig. 2A and C). The level of Annexin V + cells in peripheral blood from SLE patients was negatively correlated with C3 and C4 ( Fig. 2F and G) and positively correlated with ESR and SLEDAI scores ( Fig. 2E and H) . Interestingly, flow cytometry analysis demonstrated significantly higher Tim-3 expression on CD14 + monocytes in SLE patients than those of control subjects (Fig. 2B and  D) . The gating strategies for identification of Tim-3 expression on CD14 + monocytes were shown in Supplemental Fig. 2 . Correlation analysis showed that Tim-3 on CD14 + monocytes was negatively correlated with Annexin V + cells in control subjects (Fig. 2I) . However, Tim-3 on CD14 + monocytes was positively correlated with Annexin V + cells in peripheral blood from SLE patients (Fig. 2J) , indicating the defects of Tim-3-mediated engulfment of apoptotic cells in SLE patients, which might play roles in SLE progression. Constantly, Tim-3 on CD14 + monocytes positively correlated with anti-dsDNA levels, one of the important markers for SLE progression (Fig. 2K) . All of these results indicated that Tim-3 on CD14 + monocytes mediated engulfment of apoptotic cells in normal immune environments; however, the effect of Tim-3-promoted phagocytosis of apoptotic cells was inhibited by some unknown factors in SLE patients.
sTim-3 is elevated in SLE patients, and pretreatment of apoptotic cells with plasma from SLE patients decreases hTim-3-initiated phagocytosis of apoptotic cells
To evaluate the role of sTim-3 in the pathogenesis of SLE, we then detected plasma sTim-3 in SLE patients and control subjects. To our interest, the concentration of sTim-3 in the plasma of SLE patients was significantly higher than that of control subjects (Fig. 3A) . To explore whether sTim-3 was produced by ectodomain shedding products of ADAM-10 and ADAM-17, we detected the ADAM-10 and ADAM-17 mRNA expression in PBMCs from SLE patients by quantitative RT-PCR.
Significantly increased ADAM-10 mRNA expression was shown in Fig. 3B ; however, ADAM-17 mRNA expression showed no difference (data not shown). Previous studies have suggested antagonistic properties of sTim-3. To confirm further the effect of sTim-3 on apoptotic clearance mediated by hTim-3, we confirmed that Tim-3 was expressed on THP-1 cells and greatly up-regulated when incubated with PMA (Fig. 3C) . Apoptotic cells were incubated in the presence of 20% plasma from SLE patients or control subjects for 60 min and then cocultured with adherent-differentiated THP-1 cells by PMA. Compared with the control group, plasma from SLE patients greatly decreased phagocytosis of apoptotic cells by adherent-differentiated THP-1 cells (Fig. 3D and E) . Importantly, anti-Tim-3 antibody depletion significantly reversed the decreased phagocytosis efficiency of adherent-differentiated THP-1 cells induced by plasma from SLE patients (Fig. 4A and B) , supporting the hypothesis that sTim-3 could be antagonistic against the effect of surface Tim-3 initiating the phagocytosis of apoptotic cells.
Pretreatment of apoptotic cells with recombinant sTim-3 decreases hTim-3-initiated phagocytosis of apoptotic cells
To confirm further the hypothesis that sTim-3 could be antagonistic against the effect of surface Tim-3 initiating the phagocytosis of apoptotic cells, recombinant sTim-3 was added to the apoptotic cells for 60 min and then cocultured with adherentdifferentiated THP-1 cells by PMA. Compared with the control group, the addition of recombinant sTim-3 greatly decreased phagocytosis of apoptotic cells by adherent-differentiated THP-1 cells (Fig. 4C and D) . All of these results confirmed that sTim-3 was antagonistic against the effect of surface Tim-3 initiating the phagocytosis of apoptotic cells.
DISCUSSION
Tim-3 has been associated with immune-related diseases, cancer, and viral infections [31] [32] [33] . Accumulate data have suggested the involvement of Tim-3 in the pathogenesis of SLE [24, 34] ; however, the mechanism has not yet been identified. Here, for the first time, we provide evidence of involvement of Tim-3 in SLE by regulating apoptotic cells' engulfment of monocytes/ macrophages.
Consistent with DeKruyff et al. [23] , we confirmed that hTim-3 was a receptor for PS and could mediate the engulfment of apoptotic cells, and for the first time, we found that the IgV domain, mucin domain, and cytoplasmic domain of hTim-3 all contributed to the engulfment of apoptotic cells. Furthermore, R111 was the key site for hTim-3 to promote engulfment of apoptotic cells. Both full-length Tim-3 on CD14 + monocytes and sTim-3 in plasma of SLE patients were augmented expressed. Contrary to control subjects, Tim-3 expression on CD14 The TIM family is composed of type I cell-surface glycoproteins with common structural features, including Ig-like domain, mucin domain, transmembrane, and cytoplasmic domain. Recent reports also show that both IgV domain and mucin domain are necessary for ligand binding [35, 36] . All of the IgV domains with a long FG-CC9 loop folded back onto the GFC b-sheet, which is held in place by 2 disulfide bonds formed by the 4 noncanonical cysteine residues found in all of the TIM proteins, are used for recognition of PS [22, 23] . There is also evidence that hTim-3 is found to be a receptor for PS and could bind apoptotic cells expressing PS [23] . However, the key domain or site for hTim-3, responsible for engulfment of apoptotic cells, is still unknown. In this study, we confirmed that hTim-3 could mediate the engulfment of apoptotic cells, and both IgV and mucin domain, particularly R111, located around the FG-CC9 loop, were essential for recognition of PS. We also confirmed that the cytoplasmic domain of hTim-3 contributed to engulfment of apoptotic cells. All of these results suggest that hTim-3 indeed can bind to PS and mediate the engulfment of apoptotic cells with the help of the IgV domain, mucin domain, and cytoplasmic tail, especially R111. Until now, how Tim-3 interacts and/or cooperates with the downstream signals, allowing for the uptake of apoptotic cells, is still unknown. There are 6 conserved tyrosine residues in the hTim-3 cytoplasmic tail (Y227, Y265, Y272, Y280, Y281, Y283), which might couple to intracellular signaling pathways [35] . However, the key region or point of hTim-3 for intracellular signal transduction still remains unknown. To explore further the key cytoplasmic domain for signal transduction, T1 (containing aa 1-277), T2 (containing aa 1-264), and the points mutation plasmids (Y265F, Y272F, and Y265/272F; the number indicates the mutation site) were constructed. The engulfment of HEK293 cells transfected with the T1 construct was comparable with that of Tim-3-FL, whereas HEK293 cells, transfected with the shorter T2 plasmid, were similar to that of Dcyto. Therefore, we supposed that the functional fragment in the cytoplasmic tail of Tim-3, responsible for engulfment of apoptotic cells, is located at the region from aa 265 to 277. There are 2 tyrosine sites (Y265 and Y272) among aa 265-277 in hTim-3. To investigate the role of the individual tyrosine residues, hTim-3 constructs with mutation at Y265/Y272 were prepared and transfected into HEK293 cells for phagocytosis of apoptotic cells. Flow cytometry assay showed that mutation either at Y265 or Y272 did not affect the ability of hTim-3-mediated HEK293 cells' engulfment of apoptotic cells, and fulllength Tim-3 carrying the Y265/272F double mutation did not show a greatly weakened ability either, and it was still higher than the Dcyto (Supplemental Fig. 1E ). These data suggested that some other sites responsible for the hTim-3-mediated engulfment of apoptotic cells need further exploration. It is reported that apoptotic receptors bind directly to PS and initiate the engulfment of apoptotic cells in various intracellular signaling events, including cytoplasmic adaptor protein GULP and ELMO/Dock180/Rac pathway, which is a conserved signalling module for promoting the internalization of apoptotic cell corpses [37] [38] [39] . Whether those intracellular signaling molecules take part in the engulfment of apoptotic cells mediated by hTim-3 requires further exploration.
Extensive evidence indicates that impaired apoptotic cell clearance contributes to autoimmunity in SLE patients. Experiment data suggest that peripheral blood cells of patients with SLE exhibit increased susceptibility toward apoptosis [3, 30] . Consistently, our data also show that apoptotic cells are greatly increased in SLE patients. Moreover, the percentage of peripheral apoptotic cells is positively correlated with disease activity of SLE. As we have known, rapid removal of apoptotic cells by phagocytes is critical for the prevention of autoimmunity [29, 40] , whereas the clearance of apoptotic material by macrophages is defective in SLE [41] [42] [43] . Accumulate data have identified Tim-3 as an immune regulator on macrophages in a series of diseases [21, 44, 45] . To our interest, in this study, we found that Tim-3 expression was increased both on CD14 + cells and in plasma of SLE patients. Although sTim-3 expression levels are different from the results of Yuan et al. [28] , our results are supported by increased expression of ADAM-10 in PBMCs of SLE patients compared with control subjects. Except splicing, sTim-3 can also be produced by ectodomain shedding of ADAM-10 and -17 [27] . Increased ADAM-10 mRNA expression in PBMCs from SLE patients indicates that ADAM-10 might be responsible for the cleavage of Tim-3 from the surface of PBMCs. Of course, further investigation requires verification of the role of ADAM-10 in shedding Tim-3 by using an ADAM-10 inhibitor. The upregulated expression of full-length Tim-3 may be a result of activation of peripheral immune cells in SLE. Studies reveal the overactivation of T cells and monocytes/macrophages in SLE [46] , which might, in turn, induce Tim-3 expression. Otherwise, some serum factors in SLE might directly up-regulate Tim-3 expression, such as we have confirmed in our previous study [47] . However, the defined factors that are responsible for the induction of Tim-3 expression in SLE need to be explored further.
Of our interest, our data yield the following observations: Tim-3 expression on CD14 + monocytes was negatively correlated with the percentage of Annexin V + cells in control subjects. However, augmented Tim-3 expression on CD14 + monocytes in SLE patients showed a positive correlation with the percentage of Annexin V + cells and anti-dsDNA. All of these suggest a dysfunctional effect of Tim-3 on CD14 + monocytes in mediating the engulfment of apoptotic cells in SLE. Previous studies have suggested antagonistic properties of sTim-3. Recombinant mouse sTim-3 inhibited T cell responses to antigen-specific stimulation [31] . Recent studies have indicated that the sTim-3 could be shed from the CD8 + lymphocytes and the monocytes, and its inhibitory function has been confirmed [25, 27] . sTim-3 shedding from CD8 + T cells is involved in HIV infection and functions as a coinhibitory receptor [25] . Consistently, in this study, we found that both the addition of plasma from SLE patients, which contains up-regulated sTim-3, and the addition of recombinant sTim-3 greatly decreased the engulfment of apoptotic cells by adherent-differentiated THP-1 cells. Furthermore, sTim-3 depletion with the anti-Tim-3 antibody reversed the decreased phagocytosis of apoptotic cells induced by plasma from SLE patients. All of these data further suggest that Tim-3 on CD14 + cell-mediated engulfment of apoptotic cells could be inhibited by sTim-3 in SLE patients. However, the defined role of sTim-3 in SLE needs further exploration.
In conclusion, we have shown that hTim-3 functions in its recognition of PS and clearance of apoptotic cells by its key domains and amino acid site. These findings establish a new paradigm for Tim-3 as a PS receptor, which was associated with SLE. A significant positive correlation between Tim-3 expression and Annexin V + cells in SLE has been revealed in our data. Here is the first report that sTim-3 is elevated in plasma of SLE patients. Our data provide the hypothesis that sTim-3 may compete with Tim-3 on CD14 + cells for the PS, inhibit the clearance of apoptotic cells, and promote the pathogenesis of SLE. This study demonstrates the potential role of Tim-3 in understanding SLE mechanisms and developing therapeutic approaches. AUTHORSHIP L.G. and C.M. designed the study and conducted data analysis. D.Z., M.G., B.L., and Q.L. performed the experiments. Q.Z., X.J., and Q.S. helped in patient recruitment and in data analysis. T.X. and X.L. helped in data analysis and in developing study methods. D.Z., L.G., and C.M. authored and edited the manuscript.
